RESUMO
A drug monitoring programme has evaluated flexibility in the use of treatment intervals with Depot Fluphenazine. In this large group of schizophrenics over 30% receive injections at intervals of over 3 weeks or longer, with an overall relapse rate of 24%. Analysis of the intervals reveals in those who relapse, that 20% of cases increased their interval by an average of 7 weeks. Generally, there was an increase in intervals by the patients in the second year of treatment.
Assuntos
Flufenazina/análogos & derivados , Esquizofrenia/tratamento farmacológico , Fatores Etários , Doença Crônica , Feminino , Flufenazina/administração & dosagem , Flufenazina/sangue , Seguimentos , Humanos , Masculino , Readmissão do Paciente , Recidiva , Fatores Sexuais , Fatores de TempoRESUMO
Three aspects of treatment with injectable neuroleptics, are presented. An individualized approach to the dosage of Fluphenazine decanoate must be practiced in conjunction with, and taking into account the time spent in treatment and the sex and age variables reported. Our flexible approach to the interval between injections, indicated a large group could be maintained at intervals of 5 to 8 weeks. Complex and challenging problems can be found with antiparkinsonian drugs; 30% of nearly 400 outpatients still require these drugs.
Assuntos
Flufenazina/administração & dosagem , Transtornos Mentais/tratamento farmacológico , Adulto , Fatores Etários , Idoso , Antiparkinsonianos/administração & dosagem , Austrália , Doença Crônica , Decanoatos , Preparações de Ação Retardada , Esquema de Medicação , Discinesia Induzida por Medicamentos/prevenção & controle , Feminino , Flufenazina/efeitos adversos , Humanos , Masculino , Pessoa de Meia-Idade , Ambulatório Hospitalar , Esquizofrenia/tratamento farmacológico , Fatores SexuaisAssuntos
Psicotrópicos/efeitos adversos , Adulto , Fatores Etários , Idoso , Acatisia Induzida por Medicamentos , Discinesia Induzida por Medicamentos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Doença de Parkinson Secundária/induzido quimicamente , Fenotiazinas/efeitos adversos , Fatores SexuaisRESUMO
Most schizophrenics become in-patients in State mental hospitals, and most improve on neuroleptic medication and are rapidly discharged. The majority require long-term medication; the single most important factor in maintaining remission. This paper describes a mirror-image study using patients as their own controls, and demonstrates the highly significant differences in hospitalization before and after the administration of a depot phenothiazine. It highlights the need for vigorous and determined out-patient follow-up. It is suggested that the costs of an adequately staffed clinic are still small when compared with the costs of hospitalization. Subgroups of poor drug-responders, sex differences, variations in side effects and frequency of administration of the depot drug require further evaluation.
Assuntos
Flufenazina/uso terapêutico , Readmissão do Paciente , Esquizofrenia/tratamento farmacológico , Adolescente , Adulto , Idoso , Doença Crônica , Custos e Análise de Custo , Preparações de Ação Retardada , Feminino , Flufenazina/administração & dosagem , Humanos , Tempo de Internação , Masculino , Pessoa de Meia-Idade , Fatores SexuaisRESUMO
This Mirror Image Study, at a specialised clinic, has shown a significant reduction in days spent in Hospital. Individual features of the sample include sex and age difference in the sub-groups for dosage, duration of treatment and anti-Parkinsonian medication. Preliminary cost-effectiveness analysis has been reported.
